ClinicalTrials.gg
RecruitingNCT07153445ATHENEAUpdated Nov 19, 2025

Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)

A Phase 2 interventional study of Atezolizumab and Paclitaxel in Non Small Cell Lung Cancer, Stage IIIA Lung Cancer and Stage IIIB Lung Cancer, sponsored by Fundación GECP. Recruiting at 21 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-19.

Sponsored by Fundación GECP · Phase 2, Interventional, and Treatment

How we know · 7 judgments

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
97
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies testing atezolizumab in Carcinoma, Non-Small-Cell Lung — 13 open to participants now, 27 under way, 5 of them phase 3. atezolizumab · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
39th of 81
97 · median 80
Started
2025
with 4 others
Phase 2
48 of 81
8 open now
Primary completion
2035-05
later than 26 of 26 live
Registered
77th of 81
by date
Lead sponsor
4 of 81
Fundación GECP

Among the 81 studies testing atezolizumab in Carcinoma, Non-Small-Cell Lung, this one is the 39th largest by planned enrollment, is one of 5 that started in 2025, is one of 48 in phase 2, reaches primary completion later than 26 of the 26 other live ones, and was the 77th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

13 of the 81 studies testing atezolizumab in Carcinoma, Non-Small-Cell Lung are open now, in 6 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About atezolizumab

atezolizumab: first FDA approval 2016 (TECENTRIQ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies testing atezolizumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is an open-label, phase II, multi-centre clinical trial. 97 Patients with stage IIIA and IIIB non-small cell lung cancer will be enrolled.

The treatment is Atezolizumab + Paclitaxel + Carboplatin 3 cycles as neoadjuvant/induction treatment. After the induction treatment every patient will be evaluated by a multidisciplinary team in each participant hospital to decide if the patient is candidate for surgery or not.

Depending on the decision each patient will be treated in a different way. The primary objective is to evaluate the Progression free survival (PFS). The total trial duration will be 10 years approximately. Patient accrual is expected to be completed within 2 years. Two years of treatment, 5 years of follow up, and 4-6 months of close-out.

Read the detailed description

The study ATHENEA is a phase II clinical trial intending to enroll 97 patients, who will receive Atezolizumab + Paclitaxel + Carboplatin as induction/neoadjuvant treatment. After the induction treatment all patients will be evaluated by a multidisciplinary team in each participant hospital to decide if the patient is candidate for surgery or not.

Depending on the decision each patient will be treated in a different way.

The study is an open-label, phase II, multicenter clinical trial for previously untreated adult patients with stage to IIIA and IIIB non-small cell lung cancer.

The primary objective is to evaluate the Progression free survival (PFS) in the intent-to-treat population.

Progression free survival (PFS) defined as the time from initiation of treatment to the occurrence of disease progression or death.

The total trial duration will be 10 years approximately. Approval-start up: 4-6 months. Patient accrual is expected to be completed within 2 years. Two years of treatment, 5 years of follow up, and close-out: 4-6 months. The study will end once survival follow-up has concluded.

03

Conditions studied

  • Non Small Cell Lung Cancer
  • Stage IIIA Lung Cancer
  • Stage IIIB Lung Cancer

Keywords

  • Non small cell lung cancer
  • Atezolizumab
  • Non-resected lung cancer
  • Adjuvant treatment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previously untreated patients with - or cytologically- documented Non Small-Cell Lung Cancer (NSCLC) who present stage IIIA - IIIB disease (according to 8th version of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology)
  • Confirm the absence of distant disease
  • (Performance status) 0-1
  • Adequate hematologic and organ function
  • All patients are notified of the nature of this study and signed a written in-formed consent in accordance with institutional and national guidelines, including the Declaration of Helsinki prior to any trial-related intervention
  • Adequate lung function
  • Patients aged > 18 years
  • For female patients of , agreement (by patient and/or partner) to use a highly effective form(s) of
  • For male patients with female partners of childbearing potential, agreement (by patient and/or partner) to use a highly effective form of contraception
  • Oral contraception should always be combined with an additional contraceptive method
  • Women who are not or surgically sterile must have a negative serum pregnancy test result within 8 days prior to initiation of study drug.
  • Patient capable of proper therapeutic compliance and accessible for correct follow-up

Exclusion criteria

Exclusion Criteria:

  • Patients mutation or an amplification in the EGFRgene, ALK fusion oncogene.
  • Known STK-11 ligand alterations, MDM2 amplifications or ROS1 translocations.
  • Weight loss >10% within the previous 3 months.
  • Patients that receive previous treatment with antineoplasic drugs, chest radiotherapy, or previous surgery for lung cancer.
  • other than Non Small-Cell Lung Cancer (NSCLC) within 3 years prior to enrolment
  • Pleural or pericardial effusion
  • Known or allergy to atezolizumab formulation.
  • History of disease or lung disease
  • Positive test for human immunodeficiency viruses ()
  • Patients with active or or psitive for hepatitis C virus.
  • Active tuberculosis.
  • Symptomatic neuropathy grade > 1 according to (CTCAE) v5.0
  • Severe infections within 4 weeks prior to be included in the study
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
97 participants (estimated)

Study arms

  • Experimental
    Experimental: Neoadjuvant/Induction treatment

    Neoadjuvant/Induction treatment prior to surgery: * Atezolizumab * Paclitaxel: * Carboplatin After assessment by a multidisciplinary team who will decide on the best post-induction treatment

    Drug: Atezolizumab · Drug: Paclitaxel · Drug: Carboplatin

Interventions

  • Patients will receive atezolizumab administered by intravenous infusion in a monitored setting where there is immediate access to trained personnel and adequate equipment/medicine to manage potentially serious reactions.

    Also known as: Tecentriq

  • Neoadjuvant / induction treatment: Atezolizumab Paclitaxel Carboplatin Neoadjuvant / induction treatment 3 cycles will be administered prior to the assessment for surgery. Route of administration Paclitaxel: Intravenous infusion. Guidelines of Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml.

    Also known as: Taxol

  • Neoadjuvant / induction treatment: Atezolizumab Paclitaxel Carboplatin\* \*Infusion according to the standard of each center Neoadjuvant / induction treatment 3 cycles will be administered prior to the assessment for surgery. Route of administration Carboplatin: Intravenous infusion. Guidelines of Carboplatin administration: According to the standard of each center.

    Also known as: Paraplatin

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    Progression free survival (PFS) defined as the time from initiation of treatment to the occurrence of disease progression or death. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: From the date of randomization until end of follow up, up to 60 months.

Secondary outcomes

  1. Resectability rate (%)

    Resectability rate defined as the percentage of patients resected divided by the total number of patients who received neoadjuvant treatment.

    Time frame: From the date of randomization until end of follow up, up to 60 months.

  2. Pathological complete response (pCR)

    Pathological complete response (pCR) is defined as the absence of residual viable tumor on hematoxylin and eosin evaluation of the complete resected specimen

    Time frame: From the date of randomization until end of surgery, up to 6 months

  3. Overall survival (OS)

    Overall survival (OS) defined as the time which begins at the start of treatment and up to the time of death or last follow up

    Time frame: From the date of randomization until end of follow up, up to 60 months.

07

Study locations

20 of 21 sites recruiting
  • Hospital General Universitario Dr. Balmis de Alicante
    Alicante, Alicante 03010, Spain
    Recruiting
    • Bartomeu Massuti, MD · Contact
    • Bartomeu Massuti, MD · Principal investigator
  • ICO Badalona, Hospital Germans Trias i Pujol
    Badalona, Barcelona 08916, Spain
    Recruiting
    • Enric Carcereny, MD · Contact
    • Enric Carcereny, MD · Principal investigator
  • Hospital Universitari Vall d' Hebron
    Barcelona, Barcelona 08035, Spain
    Recruiting
    • Alex Martínez, MD · Contact
    • Alex Martínez, MD · Principal investigator
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, Barcelona 08041, Spain
    Recruiting
    • Sergio Martínez Recio, MD · Contact
    • Sergio Martínez Recio, MD · Principal investigator
  • Hospital Parc Taulí
    Barcelona, Barcelona 08208, Spain
    Recruiting
    • Laia Vilà, MD · Contact
    • Laia Vilà, MD · Principal investigator
  • Hospital De Basurto
    Bilbao, Bilbao 48013, Spain
    Recruiting
    • Mª Ángeles Sala, MD · Contact
    • Mª Ángeles Sala, MD · Principal investigator
  • Hospital Univ. De Jerez De La Frontera
    Jerez de la Frontera, Cadiz 11407, Spain
    Recruiting
    • Mª Angeles Moreno, MD · Contact
    • Mª Angeles Moreno, MD · Principal investigator
  • ICO Girona, Hospital Josep Trueta
    Girona, Girona 17007, Spain
    Recruiting
    • Elia Sais, MD · Contact
    • Elia Sais, MD · Principal investigator
  • Hospital Universitario Clinico San Cecilio
    Granada, Granada 18007, Spain
    Recruiting
    • Silvia Sequero López, MD · Contact
    • Silvia Sequero López, MD · Principal investigator
  • Hospitalario Universitario A Coruña
    A Coruña, La Coruña 15006, Spain
    Recruiting
    • Rosario García Campelo, MD · Contact
    • Rosario García Campelo, MD · Principal investigator
  • Hospital Universitari de Gran Canària Doctor Negrín
    Las Palmas de Gran Canaria, Las Palmas 35010, Spain
    Recruiting
    • David Aguiar Bujanda, MD · Contact
    • David Aguiar Bujanda · Principal investigator
  • Hospital Universitario Lucus Augusti
    Lugo, Lugo 27003, Spain
    Recruiting
    • Begoña Campos, MD · Contact
    • Begoña Campos, MD · Principal investigator
  • Hospital Universitario Fundación Jiménez Díaz
    Madrid, Madrid 28040, Spain
    Not yet recruiting
    • Manuel Dómine, MD · Contact
    • Manuel Dómine, MD · Principal investigator
  • Hospital Universitario Puerta de Hierro
    Majadahonda, Madrid 28222, Spain
    Recruiting
    • Mariano Provencio, MD · Contact
    • Clara Salas, MD · Principal investigator
  • Hospital Universitari Son Llatzer
    Palma de Mallorca, Palma de Mallorca 07198, Spain
    Recruiting
    • Ester Gost, MD · Contact
    • Juan Coves Sarto, MD · Principal investigator
  • Complejo Hospitalario de Navarra
    Pamplona, Pamplona 31008, Spain
    Recruiting
    • Maite Martínez, MD · Contact
    • Maite Martínez, MD · Principal investigator
  • Hospital Universitario Salamanca
    Salamanca, Salamanca 37007, Spain
    Recruiting
    • Alejandro Olivares Hernández, MD · Contact
    • Alejandro Olivares Hernández, MD · Principal investigator
  • Hospital Universitario Nuestra Señora La Candelaria
    Santa Cruz de Tenerife, Santa Cruz de Tenerife 38009, Spain
    Recruiting
    • Karla Mercedes Medina, MD · Contact
    • Karla Mercedes Medina, MD · Principal investigator
  • Hospital Universitario Virgen Del Rocio
    Seville, Sevilla 41013, Spain
    Recruiting
    • Reyes Bernabé, MD · Contact
    • Reyes Bernabé, MD · Principal investigator
  • Hospital Universitari Sant Joan de Reus
    Reus, Tarragona 43204, Spain
    Recruiting
    • Clara Lucía Gozalvez, MD · Contact
    • Clara Lucía Gozalvez, Md · Principal investigator
  • Hospital General Universitario de Valencia
    Valencia, Valencia 46014, Spain
    Recruiting
    • Paula Espinosa, MD · Contact
    • Paula Espinosa, MD · Principal investigator
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for May 2035, 117 months after the start.

Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's planned 117 months is above that.

Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2025
First posted
Sep 4, 2025
StartActual
Jul 8, 2025
Primary completionEst.
May 2, 2035
CompletionEst.
May 2, 2035
Last update
Nov 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07153445
Lead sponsor
Fundación GECP
Responsible party
Sponsor
First posted
Sep 4, 2025
Start date
Jul 8, 2025
Primary completion
May 2, 2035 (estimated)
Completion
May 2, 2035 (estimated)
Last update
Nov 19, 2025

Study contacts

Eva Pereira
Contact
secretaria@gecp.org
+34934302006
Mariano Provencio, MD
study chair · President of Grupo Español de Cáncer de Pulmón

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atezolizumab

Start the discussion